3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Breast
1
Conditions
Breast Neoplasms
7
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Interventions
exemestane
4
entinostat
4
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
taxane
1
pertuzumab
1
pembrolizumab
1
ipatasertib
1
figitumumab
1
elacestrant
1
dactolisib
1
atezolizumab
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Lapatinib
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Breast Diseases
×
RAD1901
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled